Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Role of SCN2A c.56G/A Gene Polymorphism in Egyptian Children with Genetic Epilepsy with Febrile Seizure Plus

Author(s): Naglaa Fathy Berseem*, Essam Shawky A. E. H. Khattab, Dalia S. Saad and Sameh A. Abd Elnaby

Volume 21, Issue 5, 2022

Published on: 23 November, 2021

Page: [450 - 457] Pages: 8

DOI: 10.2174/1871527320666211004123731

Price: $65

Abstract

Background: Febrile Seizures (FS) are the most common seizures in children younger than 5 years. In the last decade, various coding and noncoding sequence variations of voltage-gated sodium channels SCN2A have been identified in patients with seizures, implying their genetic base. We aimed to evaluate the association between SCN2A c. G/A genetic polymorphism among Egyptian children with febrile seizure plus.

Methods: The present cross-sectional study was carried out on 100 epileptic infants and children, attendants of the Neurology Unit, pediatric department, Menoufia University Hospitals (Group Ι). The patients were sub-classified into two groups, according to response to anti-epileptic treatment; Group Ι a (drug responder) and Group Ι b (drug-resistant). Evenly divided number of apparently healthy, age and gender-matched children were selected as controls (Group II). A complete history, throughout the systemic examination and radiological & metabolic assessment, whenever needed was provided, all participants were genotyped for SCN2A rs17183814 polymorphism by Restriction Fragment Length Polymorphism (PCR-RFLP).

Results: Both of A allele and AA, GA genotypes of SCN2A c. 56 G/A were detected more in patients with febrile seizure plus comparison to the control group with a statistically significant difference at frequencies of 17% and 11% and 12% respectively; OR (CI95%): 10.04 (3.49-28.87) and p <0.001. On classifying epileptic patients into 2 subgroups, carriers of SCN2A rs17183814 AA genotype tended to respond poorly to Anti-epileptic Drugs (AEDs). Moreover, multivariate analysis revealed that rs17183814 A allele and positive family history of epilepsy were considered the highest predicted risk factors for the development of epilepsy; p<0.05.

Conclusion: SCN2A rs17183814 (A) allele was specifically associated with developing febrile seizure plus and could modulate the patient's response to anti-epileptic medications.

Keywords: Antiepileptic drugs, febrile seizures, GEFS+, SCN2A polymorphism, RFLP, AEDs.

« Previous
Graphical Abstract

[1]
American Academy of pediatrics, Subcommittee on febrile seizures. Febrile seizures: guidelines for the neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011; 127: 389-94.
[2]
Berkovic SF, Scheffer IE. Febrile seizures: genetics and relationship to other epilepsy syndromes. Curr Opin Neurol 1998; 11: 129-34.
[3]
Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994; 35(Suppl. 2): S1-6.
[4]
Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures+: a genetic disorder with heterogeneous clinical phenotypes. Brain 1997; 120: 479-90.
[5]
Scheffer IE, Zhang YH, Jansen FE, Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev 2009; 31(5): 394-400.
[6]
Mulley JC, Scheffer IE, Petrou S, et al. SCN1A mutations and epilepsy. Hum Mutat 2005; (25): 535-42.
[7]
Guerrini R, Cellini E, Mei D, et al. Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene. Epilepsia 2010; (51): 2474-7.
[8]
Lerche H, Weber YG, Bater H, et al. Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. Neurology 2001; (57): 1191-8.
[9]
Dibbens LM, Feng HJ, Richards MC, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 2004; (13): 1315-9.
[10]
Orrico A, Galli L, Grosso S, et al. Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150 Italian patients with idiopathic childhood epilepsies. Clin Genet 2009; (75): 579-81.
[11]
Sugawara T, Tsurubuchi Y, Agarwala KL, et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci USA 2001; (98): 6384-638.
[12]
Barela AJ, Waddy SP, Lickfett JG, Hunter J, Anido A, Helmers SL. An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability. J Neurosci 2006; 26(10): 2714-23.
[13]
Nabbout R, Gennaro E. spectrum of SCN1A mutations severe myoclonic epilepsy of infancy. Neurology 2003; 60(12): 1961-7.
[14]
Ohmori I. Ouchida M, Ohtsuka, Y, Oka E, Shimizu K. Significant correlation of The SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun 2002; (295): 17-23.
[15]
Engel J. Report of the ILAE Classification Core Group. Epilepsia 2006; 47(9): 1558-68.
[16]
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58(4): 522-30.
[17]
Annegers JF, Blakley SA, Allen H, Kurland W. Recurrence of febrile convulsions in a population-based cohort. Epilepsy Res 1990; (5): 209-16.
[18]
Arzimanoglou A, Berg AT, Brodie MJ, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51(6): 1069-77.
[19]
Zhang YH, Burgess R, Malone JP, et al. Genetic epilepsy with febrile seizures plus: refining the spectrum. Neurology 2017; 89(12): 1210-9.
[20]
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, DeJonghe P. De novo mutations in the sodium-channel gene scn1a cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68(6): 1327-32.
[21]
Bonanni P, Malcarne M, Moro F, et al. Generalized epilepsy with febrile seizures plus (GEFS1): clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B and GABRG2 gene mutations. Epilepsia 2004; 45: 149-58.
[22]
Yasumoto S,. Shi X, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev 2009; 31(10): 758-62.
[23]
Nordli DR Jr, Pellock JM, Sankar R, Wheless JW, Eds. 2016.
[24]
Nakayama YN, Hamano K, Iwasaki N, Ohta M. Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans. Neurosci Lett 2002; 329: 249-51.
[25]
Javadi MS, Naseri R, Moshfeghi S, Allahyari I, Izadi V, Mohammadi R. Etiology, Epidemiologic Characteristics and Clinical Pattern of Children with Febrile Convulsion Admitted to Hospitals of Germi and Parsabad towns in 2016. World Family Medicine Journal: Incorporating the Middle East Journal of Family Medicine 2017; 99(5480): 1-6.
[26]
Pavlidou E, Hagel C, Panteliadis C. Febrile seizures: recent developments and unanswered questions. Childs Nerv Syst 2013; 29(11): 2011-7.
[27]
Byeon JH, Kim GH, Eun BL. Prevalence, incidence, and recurrence of febrile seizures in Korean children based on national registry data 2018; 14(1): 43-7.
[28]
Ojha AR, Shakya KN, Aryal UR. Recurrence risk of febrile seizures in children. J Nepal Paediatr Soc 2012; 32(1): 33-6.
[29]
Mwipopo EE, Akhatar S, Fan P, Zhao D. Profile and clinical characterization of seizures in hospitalized children. Pan Afr Med J 2016; 24.
[30]
Hwang G, Kang HS, Park SY, Han KH, Kim SH. Predictors of unprovoked seizure after febrile seizure: short-term outcomes 2015; 37(3): 315-21.
[31]
Fallah R, Karbasi SA. Recurrence of febrile seizure in Yazd, Iran. Turk J Pediatr 2010; 52(6): 618.
[32]
Wang X, Xu M, Du L. 2007.
[33]
Baum L, Haerian BS, Ng HK, et al. Case–control association study of polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, SCN3A, SCN1B, and SCN2B and epilepsy. Human genetics 2014; 133(5): 651-9.
[34]
Ito M, Shirasaka Y, Hirose S, Sugawara T, Yamakawa K. Seizure phenotypes of a family with missense mutations in SCN2A. Pediatr Neurol 2004; 31: 150-2.
[35]
Chentouf A, Talhi R, Dahdouh A, Benbihi L, Benilha S, Oubaiche ML. Consanguinity and epilepsy in Oran, Algeria: A case- control study. Epilepsy Res 2015; (111): 10-7.
[36]
Masri A, Hamamy H. Clinical and inheritance profile of familial childhood epilepsy in Jordan. Seizure 2013; 22(6): 443-51.
[37]
Sozmen V, Baybas S, Dirican A, Koksal A, Ozturk M. Frequency of epilepsies in family members of patients with different epileptic syndromes. Eur Neurol 2011; 65(1): 4-9.
[38]
Laith NA, Islam MA, Hanan AA. Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility. Saudi Pharm J 2019; 27(5): 731-37.
[39]
Pejanovic-Skobic N, Markovic I, Bozina N, Basic S. Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. Epilepsy research 2019. 158: 106221.
[40]
Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain 2017; (140): 1316-36.

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy